The seven Covid hotspots right now - is your area one of them?
It's not yet clear if the strain has made it to the UK, with surveillance ongoing.
Amesh Adalja, a public-health expert at the Johns Hopkins Center for Health Security said: "It [XBB] is likely the most immune-evasive [subvariant] and poses problems for current monoclonal antibody-based treatments and prevention strategy. "Even with immune-evasive variants, vaccine protection against what matters most – severe disease – remains intact."In a statement Dr Meera Chand, Director of Clinical and Emerging Infections at the UKHSA said: “UKHSA continues to monitor and assess all emerging SARS-CoV-2 variants, both in the UK and around the world.
"As we head into winter and cases rise, make sure you have any Covid-19 vaccinations you are eligible for and avoid contact with others if you are unwell or have symptoms of a respiratory infection.” As medics urge people to come forward for their jabs, campaigners and charities have asked the government toMany of these people were unable to have a jab due to medical reasons.It's made by AstraZeneca and was approved by the medicines regulator in March.Despite its widespread use, the UK government said it won't buy more doses until it has more data.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Comparison of Long-Term Complications of COVID-19 Illness among a Diverse Sample of Children by MIS-C StatusMost pediatric COVID-19 cases are asymptomatic; however, a small number of children are diagnosed with multisystem inflammatory syndrome in children (MIS-C), a rare but severe condition that is associated with SARS-CoV-2 infection. Persistent symptoms of COVID-19 illness in children diagnosed with/without MIS-C is largely unknown. A retrospective EHR review of patients with COVID-19 illness from one pediatric healthcare system to assess the presence of acute (<30 days) and chronic (≥30, 60–120, and >120 days) long-term COVID symptoms was conducted. Patients/caregivers completed a follow-up survey from March 2021 to January 2022 to assess the presence of long COVID. Results showed that non-MIS-C children (n=286; 54.49% Hispanic; 19.23% non-Hispanic Black; 5.77% other ethnicity; 79.49% government insurance) were younger (mean age 6.43 years [SD 5.95]) versus MIS-C (n=26) children (mean age 9.08 years, [SD 4.86]) (p=0.032). A share of 11.5% of children with MIS-C and 37.8% without MIS-C reported acute long COVID while 26.9% and 15.3% reported chronic long COVID, respectively. Females were almost twice as likely to report long symptoms versus males and those with private insurance were 66% less likely to report long symptoms versus those with government insurance. In conclusion, a substantial proportion of ethnically diverse children from low resource backgrounds with severe COVID illness are reporting long-term impacts. Findings can inform pediatric professionals about this vulnerable population in post-COVID-19 recovery efforts.
Læs mere »
Do phthalates in face masks pose health hazards with increased usage during the COVID-19 pandemic?In a new study, researchers investigated the presence of phthalic acid esters (PAEs) or phthalates in commercially available face masks to assess the health risks associated with the increased use of face masks during the coronavirus disease 2019 (COVID-19) pandemic.
Læs mere »
What is the impact of COVID-19 and organophosphates on cardiac health?In a new study, researchers discussed the impacts of organophosphates (OP) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on cardiovascular (CVS) health.
Læs mere »
Physical exercise provides positive health benefits on COVID-19 outcomesPhysical exercise provides positive health benefits on COVID-19 outcomes PLOSONE COVID19 SARSCoV2 Exercise PhysicalActivity
Læs mere »
Taking stock of mental health trends in the U.S. during the COVID-19 pandemicA new study posted in the pre-print server medRxiv* aimed to apply clustering and network analysis to determine the connectivity between the states and used COVID-19-related mental health indicators to understand how COVID-19 impacts mental health across the United States.
Læs mere »
Pathophysiology of Post-COVID syndromes: a new perspective - Virology JournalMost COVID-19 patients recovered with low mortality; however, some patients experienced long-term symptoms described as “long-COVID” or “Post-COVID syndrome” (PCS). Patients may have persisting symptoms for weeks after acute SARS-CoV-2 infection, including dyspnea, fatigue, myalgia, insomnia, cognitive and olfactory disorders. These symptoms may last for months in some patients. PCS may progress in association with the development of mast cell activation syndrome (MCAS), which is a distinct kind of mast cell activation disorder, characterized by hyper-activation of mast cells with inappropriate and excessive release of chemical mediators. COVID-19 survivors, mainly women, and patients with persistent severe fatigue for 10 weeks after recovery with a history of neuropsychiatric disorders are more prone to develop PCS. High D-dimer levels and blood urea nitrogen were observed to be risk factors associated with pulmonary dysfunction in COVID-19 survivors 3 months post-hospital discharge with the development of PCS. PCS has systemic manifestations that resolve with time with no further complications. However, the final outcomes of PCS are chiefly unknown. Persistence of inflammatory reactions, autoimmune mimicry, and reactivation of pathogens together with host microbiome alterations may contribute to the development of PCS. The deregulated release of inflammatory mediators in MCAS produces extraordinary symptoms in patients with PCS. The development of MCAS during the course of SARS-CoV-2 infection is correlated to COVID-19 severity and the development of PCS. Therefore, MCAS is treated by antihistamines, inhibition of synthesis of mediators, inhibition of mediator release, and inhibition of degranulation of mast cells.
Læs mere »